Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiretroviral-therapy-associated lipoatrophy: current status and future directions

Antiretroviral-therapy-associated lipoatrophy: current status and future directions Lipoatrophy is perhaps the most visibly recognisable component of antiretroviral-therapy-associated lipodystrophy due to the rarity of this form of body composition change in the general population. In this respect, it is apparent that lipoatrophy represents a form of drug toxicity specifically involving the subcutaneous fat tissue, resulting in pathological fat loss that preferentially affects the limbs and face. It is now clear that the choice and duration of nucleoside analogue reverse transcriptase inhibitor (NRTI) therapy (stavudine > zidovudine) is the dominant risk factor for clinical lipoatrophy, as well as for the pathological changes to adipose tissue that underlie the clinical syndrome. Host factors have also emerged as important modulators of lipoatrophy severity in patients receiving these NRTI drugs, including age, racial origin, and severity of immune deficiency. On the other hand, the use of selected HIV protease inhibitor drugs is more closely associated with metabolic complications such as dyslipidemia and insulin resistance and has not been convincingly linked to lipoatrophy. This review examines the clinical and pathological manifestations of lipoatrophy, and also presents information regarding the safety profile of alternative NRTI drugs, such as tenofovir and abacavir, that have not been associated with lipoatrophy risk. With increasing knowledge of lipoatrophy pathogenesis, it is likely that moderate and severe forms of this complication can now be considered a preventable complication of HIV treatment. However, it is also important to recognise that there is an ongoing burden of disease in patients who have been affected by lipoatrophy over the past six years, and that therapeutic management of established lipoatrophy will remain a challenge into the future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Sexual Health CSIRO Publishing

Antiretroviral-therapy-associated lipoatrophy: current status and future directions

Nolan David D.; Mallal Simon S.
Sexual Health , Volume 2 (3) – Sep 20, 2005
Download PDF
11 pages

Loading next page...
 
/lp/csiro-publishing/antiretroviral-therapy-associated-lipoatrophy-current-status-and-ivVX8j2WrL

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
CSIRO Publishing
Copyright
CSIRO
ISSN
1448-5028
eISSN
1449-8987
DOI
10.1071/SH04058
Publisher site
See Article on Publisher Site

Abstract

Lipoatrophy is perhaps the most visibly recognisable component of antiretroviral-therapy-associated lipodystrophy due to the rarity of this form of body composition change in the general population. In this respect, it is apparent that lipoatrophy represents a form of drug toxicity specifically involving the subcutaneous fat tissue, resulting in pathological fat loss that preferentially affects the limbs and face. It is now clear that the choice and duration of nucleoside analogue reverse transcriptase inhibitor (NRTI) therapy (stavudine > zidovudine) is the dominant risk factor for clinical lipoatrophy, as well as for the pathological changes to adipose tissue that underlie the clinical syndrome. Host factors have also emerged as important modulators of lipoatrophy severity in patients receiving these NRTI drugs, including age, racial origin, and severity of immune deficiency. On the other hand, the use of selected HIV protease inhibitor drugs is more closely associated with metabolic complications such as dyslipidemia and insulin resistance and has not been convincingly linked to lipoatrophy. This review examines the clinical and pathological manifestations of lipoatrophy, and also presents information regarding the safety profile of alternative NRTI drugs, such as tenofovir and abacavir, that have not been associated with lipoatrophy risk. With increasing knowledge of lipoatrophy pathogenesis, it is likely that moderate and severe forms of this complication can now be considered a preventable complication of HIV treatment. However, it is also important to recognise that there is an ongoing burden of disease in patients who have been affected by lipoatrophy over the past six years, and that therapeutic management of established lipoatrophy will remain a challenge into the future.

Journal

Sexual Health – CSIRO Publishing

Published: Sep 20, 2005

References

  • Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.
    Carr A
  • Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study.
    Palella FJ Jr
  • A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals.
    Power R
  • Metabolic effects of indinavir in healthy HIV-seronegative men.
    Noor MA
  • Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.
    Noor MA
  • Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.
    Purnell JQ
  • Switching effective antiretroviral therapy: a review.
    Dreschsler H
  • Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir.
    Haerter G
  • A syndrome of peripheral fat
    Saint-Marc T
  • Lipodystrophy in patients naive to HIV protease inhibitors.
    Madge S
  • A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A
  • Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
    Mallal SA
  • Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
    Saint-Marc T
  • Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M
  • Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study.
    Bernasconi E
  • Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.
    Heath KV
  • Antiretroviral therapy and the lipodystrophy syndrome.
    John M
  • Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.
    Chene G
  • Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: Ozcombo 1 and 2.
    Amin J
  • Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
    Joly V
  • Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
    Mallon PW
  • Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
    Nolan D
  • Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.
    Johnson AA
  • Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.
    Birkus G
  • Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
    Gallant JE
  • Objective evaluation of HIV lipodystrophy case definition in a randomized 96 week clinical trial.
    Law MG
  • Fosamprenavir/ritonavir and nelfinavir have comparable effects on body fat changes in antiretroviral-naive patients: 48-week results from the SOLO study.
    Walmsley S
  • The proportion of patients reporting body fat redistribution was unchanged between week 4 and week 120 in subjects receiving fosamprenavir/ritonavir in Study APV30005.
    Walmsley S
  • Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
    Carr A
  • Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
    McComsey GA
  • Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
    Nolan D
  • Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy.
    Lloreta J
  • Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients.
    Walker UA
  • Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Domingo P
  • Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6–12 months of commencing nucleoside reverse transcriptase inhibitor therapy.
    Hammond E
  • Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine + didanosine or zidovudine + zalcitabine) vs.
    Reiss P
  • Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion.
    Petit C
  • Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
    Miura T
  • Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.
    Hoy JF
  • Effects of sex and race on lipodystrophy pathogenesis.
    Nolan D
  • Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.
    Lichtenstein KA
  • Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
    Moore RD
  • Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
    Gerstoft J
  • Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
    Margot NA
  • The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A
  • Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
    Stone C
  • In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine.
    Bazmi HZ
  • Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
    Rifkin BS
  • Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
    Breton G
  • Renal safety of tenofovir in HIV treatment-experienced patients.
    Izzedine H
  • Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.
    Peyriere H
  • Tenofovir and how to assess renal function in patients on antiretroviral therapy.
    Mauss S
  • Reasons for early abacavir discontinuation in HIV-infected patients.
    Peyriere H
  • Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
    Hetherington S
  • Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.
    Phillips EJ
  • Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.
    Martin AM
  • Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S
  • Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
    Hetherington S
  • Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.
    Hughes DA
  • Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
    Valantin MA
  • A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.
    Moyle GJ
  • No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
    Carr A
  • Rosiglitazone in the treatment of HAART-associated lipodystrophy–a randomized double-blind placebo-controlled study.
    Sutinen J
  • Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
    Hadigan C
  • Rosiglitazone for HIV-1 lipoatrophy.
    Cavalcanti RB